BrainScope Ahead 100
Overview
The BrainScope Ahead 100 is an innovative, AI-driven medical device developed by BrainScope Company, Inc. It utilizes advanced computational neuroscience and artificial intelligence to transform brain electrical activity (EEG) into a powerful assessment tool for mild traumatic brain injury (mTBI), including both structural injuries like brain bleeds and functional injuries such as concussions. This portable, non-invasive device is designed for rapid, point-of-care use in emergency settings, aiming to provide objective diagnostic insights to aid clinicians. Its primary goal is to help reduce unnecessary head CT scans and improve patient outcomes by offering a quick and accurate initial assessment of head-injured patients. The BrainScope Ahead 100 was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven platform for EEG analysis
- Non-invasive and portable design
- Disposable electrode headset and mobile interface
- Rapid assessment at the point of care
- Aids in evaluating mild traumatic brain injury (mTBI)
- Identifies structural (brain bleeds) and functional (concussions) injuries
- Reduces unnecessary head CT scans
- Provides objective biomarkers from EEG signals
- De-noised and digitized EEG signals
- Cloud-based analytics platform for third-party EEG data integration
Use Cases
- Adjunctive assessment of mild traumatic brain injury (mTBI) in emergency departments
- Aiding clinicians in decisions regarding the necessity of a head CT scan
- Rapid identification of structural brain injuries (e.g., brain bleeds)
- Assessment of functional brain injuries (e.g., concussions)
- Reducing patient length of stay in emergency departments
- Potential for early stroke evaluation (secondary application)
What Physicians Need to Know
The BrainScope Ahead 100 is an adjunctive tool for mild TBI assessment (GCS 13-15, 18-80 years old, within 24 hours of injury) and should not replace a CT scan or serve as a standalone diagnostic. It is particularly useful for rapidly assessing the likelihood of structural brain injury or concussion at the point of care, potentially reducing unnecessary CT scans and improving patient flow in emergency settings. Physicians must input the patient's GCS score prior to initiating the test and ensure standard EEG practices are followed. Be aware of exclusion criteria, including patients with a history of stroke/TIA within the past year, seizure disorder, or GCS less than 13.
The device itself is a handheld system for EEG acquisition and analysis. The Ahead EU-100 model offers a web-based capability for centralized storage and review of patient data, implying potential for data integration with electronic health records or other hospital systems for comprehensive patient management and longitudinal tracking. BrainScope's broader platform can utilize EEG acquired from third-party devices through cloud or API applications for biomarker development, suggesting a flexible architecture for future integrations.
Details
| Category | Neurology AI, Triage & ER/ICU AI |
| Pricing | Not available publicly |
| Deployment | Portable device with mobile interface; cloud-based analytics platform available |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated The BrainScope Ahead 100 (DEN140025) was cleared by the FDA on November 17, 2014, through the de novo classification process. It is indicated as an adjunct to standard clinical practice to aid in the evaluation of patients aged 18-80 years who sustained a closed head injury within 24 hours, clinically present as a mild traumatic brain injury with a Glasgow Coma Scale (GCS) score of 13-15, and are being considered for a head CT scan. |
| Integrations | |
| EHR | Not specified |
| Specialties | Emergency Medicine, Neurology, Sports Medicine |
What the Web Says
The BrainScope Ahead 100 is an FDA-cleared, non-invasive, handheld device that uses EEG to assess mild traumatic brain injury (mTBI) and aid in the evaluation of patients being considered for a head CT scan. It is designed to provide rapid, objective information about the structural condition of the brain and can also assess brain function and concussion. Physicians have expressed positive opinions, highlighting its potential to reduce unnecessary CT scans, decrease radiation exposure, and lower healthcare costs.
Overall: PositiveStrengths
- Rapid and objective assessment of mTBI and concussion in under 20 minutes.
- Reduces unnecessary head CT scans and associated radiation exposure.
- Can decrease patient length of stay in the emergency department.
- High sensitivity (99%) in detecting brain bleeds (u22651 mL) and a high negative predictive value (98%) for ruling out structural injury.
- Portable, non-invasive, and non-radiation emitting.
- Provides objective information for concussion diagnosis and follow-up care.
Limitations
- Not a substitute for a CT scan.
- False negative rate of 21.5% and a false positive rate of 51.4% were observed in one study, though later studies claim 2% false negatives.
- Some early reviews or evaluations may have contained inaccuracies regarding its intended use or algorithm components.
- The cost per use is not yet below $100, though the company aims for it.
- Limited to patients aged 18-80 years who sustained a closed head injury within 24 hours and present with mild TBI (GCS 13-15).
Based on reviews from: FDA, Fierce Biotech, ACEP, BrainScope, PR Newswire, Maryland Daily Record, Reddit, G2
Last updated: 2026-07-18
Ratings & Reviews
Rate BrainScope Ahead 100
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for BrainScope Ahead 100.
